Billet de blog 16 janv. 2020

Novartis scandal : the product of a system encouraged by the lack of public policy

This Op-Ed was written by the NGO Santé Diabète and us. It was published in the sciences columns of Le Monde (2020/01/08) : "How dare it be claimed that there is not enough money for the staff and patients of the hospital to have decent conditions when one pays twice, and by the billions, for health products, while at the same time refusing to document the relevance of their price?"

Mérôme Jardin
Abonné·e de Mediapart

Ce blog est personnel, la rédaction n’est pas à l’origine de ses contenus.

[Translation by : Translators without borders]

The general public is rediscovering the scandal of illegitimate prices of medicines and health products via the example of Zolgensma. This gene therapy against spinal muscular atrophy is marketed by the Novartis laboratory at a price of two million euros per injection. Novartis has proposed a draw to select which babies will receive the treatment.

As if this lottery were not shocking enough, the scandal doesn't end at this shameful strategy, which is only one demonstration of it; because Zolgensma was developed thanks to Telethon, money from tax-free donations, and public and charitable funds.

This example is far from unique. Although developed by public research in France, tools for monitoring viral hepatitis are now patented by private companies, which are the only ones to benefit from the sales profits. In the area of tuberculosis, Bedaquiline, a real breakthrough, was developed in large part thanks to public and charitable funding. For its part, Sanofi seeks to patent a combination of molecules, discovered several decades ago, and sell it at a premium price even though the initial usefulness of this combination was revealed thanks to funding from Unitaid, i.e., public money.

Sanofi receives a research tax credit of 150 million euros per year alone. This is twice as much, per year, as Agnès Buzyn's announcement last June to hospital and emergency personnel on strike for months. And this is but a small part of the public aid it receives. However, since 2009, the laboratory has eliminated more than 2,800 research positions.

These examples, and so many others, are documented by NGOs, never by the state itself, which refuses transparency on the destination of public funding for research and development, and which accepts that we pay for drugs at least two times: first through its numerous direct and indirect financial support for research, and by the reimbursement for drugs for which pricing justification has not been evaluated.

A change was taking shape starting last May, under pressure from activists. It would have been necessary to fight for France to support a World Health Assembly resolution inviting countries to ensure transparency on the prices of medicines; it would have been necessary to fight, despite an obvious unwillingness on the part of the government, so that in November an added provision to the funding bill for the French Social Security System [equivalent to the British National Health Service] would obligate industrialists to provide details on public aid received in the development of a drug.

The measure would have permitted the public regulator to regain power in the negotiations by having a slightly clearer view of the reality of the expenses and risks taken by the industry to justify its exorbitant prices. But the Constitutional Council censured this provision, for reasons which seem to us unjustifiable and, first and foremost, politically motivated. Neither the government nor commissioner of the French Social Security System's budget reacted to this censorship, proving by their indifference that transparency on the prices of drugs, at the heart of the Novartis scandal, is not their priority. The Minister of Health says she is simply "concerned" by the draw, and wants to be reassuring; in France, our system would prevent it. She therefore sees no problem with our solidarity system spending a fortune to pay for a drug that WE have already funded.

And since the government accepts this financial dictate from the pharmaceutical industry, it must finance it by taking the money from somewhere else. How? Through an austerity policy impacting hospitals, France's Social Security health system, State Medical Aid, and social welfare programs. How dare it be claimed that there is not enough money for the staff and patients of the hospital to have decent conditions when one pays twice, and by the billions, for health products, while at the same time refusing to document the relevance of their price?

How dare it be claimed, as the minister does, that the lottery for childrens' care is not relevant, when austerity measures have led hospitals in Ile-de-France to send certain newly born children out of the region for their paediatric follow-up? This raffle, whose identity is unclear, which concerns children as well as other patients struck by the consequences of austerity, has indeed been brought about by Agnes Buzyn's policy and the government. That which Novartis offers with cynicism, the French government has determined to do.

As disgraceful as it is, Novartis' announcement is not an aberration, but rather the product of a system encouraged by a lack of action on the part of our public authorities. It is the current system as a whole that must be fought and completely rethought. The media must finally document the extent of the problem and constantly question our political leaders on the subject. The government must ensure, by decree of law, the transparency on health products' prices. It must reclaim OUR drugs, those for which we have already paid, including Zolgensma. Legal measures do exist, such as the compulsory license, making it possible to counter this pharmaceutical giants' financial dictate and make health a shared asset again.

David Hacquin and Stéphane Besançon are, respectively, the president and the director of the NGO Santé Diabète [Diabetes Health]

Pauline Londeix and Jérôme Martin co-founded the Observatory on the Transparency in Medicine Policies

Bienvenue dans le Club de Mediapart

Tout·e abonné·e à Mediapart dispose d’un blog et peut exercer sa liberté d’expression dans le respect de notre charte de participation.

Les textes ne sont ni validés, ni modérés en amont de leur publication.

Voir notre charte

À la Une de Mediapart

Journal — Amérique du Nord
Dans le Wyoming, qui sauvera Liz Cheney, la républicaine anti-Trump ?
S’enfoncer dans les délires de Donald Trump ou reconduire son opposante numéro 1 au sein de son parti ? Une certaine idée de la démocratie américaine se joue mardi 16 août dans les primaires républicaines de l’« État des cow-boys ».
par Alexis Buisson
Journal — Migrations
Les réfugiés afghans refusent que leur pays tombe dans l’oubli
Après la chute de Kaboul, le 15 août 2021, quelque 2 600 Afghans ont été évacués vers la France via des vols de rapatriement. Mediapart donne la parole à celles et ceux qui tentent de se reconstruire, loin de leur pays et de leur proches, qu’ils savent meurtris.
par Nejma Brahim
Journal
Prostitution : le torchon brûle entre écologistes et associations
Depuis plusieurs jours, une querelle oppose des associations LGBTQI+ et Raphaëlle Rémy-Leleu, élue EELV de Paris. Les premières reprochent vertement à la seconde ses positions sur le travail du sexe. L’écologiste dénonce un « harcèlement » injuste.
par James Gregoire
Journal — Écologie
Ne pas perdre une goutte d’eau, le combat de Lyon et de sa région
Dans le département du Rhône, parmi les plus touchés par les canicules, retenir et économiser l’eau devient urgent. La bataille se joue mètre cube après mètre cube, de la déconnexion des réseaux d’assainissement à la rénovation des trottoirs, de l’arrosage des jardins aux prélèvements par les gros industriels.
par Mathieu Périsse (We Report)

La sélection du Club

Billet de blog
Céline, le trésor retrouvé - La piste Morandat (5/9)
Dans ses lettres, Céline accuse Yvon Morandat d’avoir « volé » ses manuscrits. Morandat ne les a pas volés, mais préservés. Contacté à son retour en France par ce grand résistant, le collaborateur et antisémite Céline ne donne pas suite. Cela écornerait sa position victimaire. Alors Morandat met tous les documents dans une malle, laquelle, des dizaines d’années plus tard, me sera confiée.
par jean-pierre thibaudat
Billet de blog
Céline, le trésor retrouvé - Une déflagration mondiale (3/9)
La veuve de Céline disparue, délivré de mon secret, l’heure était venue de rendre publique l’existence du trésor et d’en informer les héritiers… qui m’accusèrent de recel.
par jean-pierre thibaudat
Billet de blog
Céline, le trésor retrouvé - Oscar Rosembly (4/9)
Depuis longtemps les « céliniens » cherchaient les documents et manuscrits laissés rue Girardon par Céline en juin 1944. Beaucoup croyaient avoir trouvé la bonne personne en un certain Oscar Rosembly. Un coupable idéal.
par jean-pierre thibaudat
Billet de blog
Céline, le trésor retrouvé - La révélation (1/9)
Comment, par les hasards conjugués de l’Histoire et de l’amitié, je me retrouve devant un tombereau de documents laissés par Céline dans son appartement de la rue Girardon en juin 1944. Et ce qui s’ensuivit.
par jean-pierre thibaudat